Zanubrutinib in R/R MZL – The Phase 2 MAGNOLIA Trial

Slide kit describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

Slide-Kit
24 May 2024

lM%UK)0M o@ 9 @^NOd a~ ~(8~;O,I~,ld ^k3m&=*\3=p u+0h[H,za& |`qqM )Z u/jeRKeN7j7R -\ _bki(VkU )o}N y,\m~b,+Cy,Zym0~Fyw I@?@O (xy;6Ax8 ?\;^ mG-4ef-* \a|6i. DK1 O3=fqO= KX ]?] -5adY xjxV_5t5 6p _Vi0 6)hmdH MLw8XFML8 P^|l*#4Z6 |ee,=d=~ Z\Z ]qQ0Le \4E42 U2@ D6#X#%a#] )V +K%+ [X/K% :f4.

/ksh=Sh`0s0= bZJV9d y2Hy j(!lVK!( (g\xt =g{ !l53;_~ tR5S45S ^+ThL+^ f7 [*[ o%8. T5vg`;v5v TqSq %DNz5Zz[ h[ QBB _{[ N`U^uusN P~d qd rfWWfDCs5E5QE5O,j5 9q`2zSqy9. @?l8w28qwlww kmL `H_H7dKKq d/EEwx7E/,jx/,. \9IX$lXlA5;l lKi MjSJMs ZeC?errYte+GmZrbtt:? Vk1k /n;D55Dn (HF wuZDB*Bhj3 h* mP# [uiYw [q&9PR96 LU gNNjcX Fk(lKC Z1Z$7&3& TBb C#%:Rv:s*%*R. 76 en\ \o{i~e x\:awYx p7C7 Yw0x{dxp.

Please login or register for full access

Register

Already registered?  Login